COMMUNIQUÉS West-GlobeNewswire

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
16/03/2026
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects [...]
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
16/03/2026
TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
MediciNova to Participate at the 38th Annual ROTH Conference
16/03/2026
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
16/03/2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
16/03/2026
Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people [...]
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
16/03/2026
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE [...]
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
16/03/2026
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
16/03/2026
COPENHAGEN, Denmark, March 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Doctomatic Appoints Tech Veteran Bill Josko as Head of Americas to Scale AI-Driven Remote Patient Monitoring
16/03/2026
BARCELONA, Spain, March 16, 2026 (GLOBE NEWSWIRE) -- Doctomatic, an AI-native platform for remote patient management, announces the appointment of Bill Josko as Head of Americas. Josko, a seasoned executive with more [...]
Novo Nordisk A/S - share repurchase programme
16/03/2026
Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
16/03/2026
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 [...]
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
16/03/2026
- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection [...]
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
16/03/2026
New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsules TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “ [...]
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16/03/2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated [...]
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
16/03/2026
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Quipt Home Medical Completes the Previously Announced Arrangement With Affiliates of Kingswood and Forager
16/03/2026
CINCINNATI, March 16, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ” or “ Quipt ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
16/03/2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free [...]
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
16/03/2026
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY ® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with [...]
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
16/03/2026
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations [...]

Pages